Ipsc Articles & Analysis: Older
49 news found
l Induced Pluripotent Stem Cells (iPSCs): iPSC-derived exosomes offer potential in personalized medicine due to their capacity to mimic patient-specific cellular environments. ...
Ace Therapeutics is proud to announce the launch of its cardiovascular disease model development services, aiming to empower researchers and pharmaceutical companies with advanced tools and models to accelerate the study of cardiovascular diseases and drug discovery. Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, underscoring the urgent need for ...
However, despite significant advancements in iPSC culture, several challenges remain regarding the reliability, reproducibility and consistency of cell cultures, assays and data. ...
Our lead product is 3D cardiac engineered heart tissues (EHTs) fabricated from human induced pluripotent stem cell (iPSC) derived cardiomyocytes. Applying induced pluripotent stem cell (iPSC) technology, patient-cell derived 3D micro tissues exhibiting hereditary cardiac diseases are mass-produced in micro wells. ...
The Microplate Reader Company – and InvivoSciences, Inc. – a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery – announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies. Employing an automated system, 3D heart ...
InvivoSciences, Inc. is an active member of the cardiac safety technical committee organized by HESI to review new technologies such as applications of human induced pluripotent stem cells (iPSC) derived cardiomyocytes for improving preclinical cardiac safety assays. ...
Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and macrophage cell therapies for various solid tumours. Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ...
Bringing together Mammoth’s novel CRISPR systems with Bayer’s existing gene augmentation and its induced pluripotent stem cell (iPSC) platforms will allow Bayer to unleash the full potential of its cell and gene therapy strategy. ...
ByBayer AG
The Company’s allogeneic (“off-the-shelf”) cell platform is based upon induced pluripotent stem cells (iPSCs) generated from donated cord blood that can be differentiated into NK cells, T cells and other cells of the immune system. The iPSCs are genetically engineered to provide enhanced function for the derived NK and other immune cells. ...
Stefan moving to a role where his unique iPSC expertise can be maximized, while partnering with Gustavo, who is so experienced at scaling technical businesses into GMP, is a potent ...
With the introduction of induced pluripotent stem cells (iPSCs) to our DeltEx platform, we possess a comprehensive suite of technologies and capabilities to target cancer with gamma-delta T cells,” stated William Ho, CEO and co-founder of IN8bio. ...
IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells. ...
“Bringing together Mammoth’s novel CRISPR systems with our existing gene augmentation and our induced pluripotent stem cell (iPSC) platforms will allow us to unleash the full potential of our cell and gene therapy strategy,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of the Bayer’s Pharmaceuticals Division. ...
Diabetes drug screening platforms using patient pancreatic islet-like cells generated from induced pluripotent stem ...
Human induced pluripotent stem cell-derived beta-cells for drug and toxicity ...
IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop cell therapies that synergize with chemotherapy to effectively identify and eradicate tumor cells. ...
IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells. ...
IN8bio also has a broad portfolio of preclinical programs including induced pluripotent stem cell (iPSC) derived gamma-delta T cells and those focused on addressing other solid tumor types. ...
Wu, co-founder of Greenstone Biosciences remarks, "This is a great collaboration that translates our expertise in iPSC technology to accelerate therapies that improve patient care – fast-tracking bench to bedside." ...
“Two major industry-wide challenges include the ability to scale iPSC-based culture while maintaining cell health, quality, and efficient immune cell differentiation. ...